XML 152 R69.htm IDEA: XBRL DOCUMENT v3.20.4
Discontinued operations (Tables)
 12 Months Ended
Dec. 31, 2020
Statement [line items]  
Respective Useful Lives of Available-for-Use Intangible Assets




Useful life
Income statement location

for amortization and

impairment charges
Currently marketed products
5 to 20 years
"Cost of goods sold"
Technologies
10 to 20 years



"Cost of goods sold"

or "Research

and development"
Other (including

computer software)
3 to 7 years

In the respective

functional expense
Defined contribution plans
(USD millions)
2020
2019
2018
Contributions for defined contribution plans continuing operations
501
422
443
Discontinued operations  
Statement [line items]  
Consolidated income statement, discontinued operations
(USD millions)
2019 1
2018
Net sales to third parties from

discontinued operations


1 777


7 149
Sales to continuing segments
32
4
Net sales from discontinued operations
1 809
7 153
Cost of goods sold
– 860
– 3 983
Gross profit from discontinued operations
949
3 170
Selling, general and administration
– 638
– 2 754
Research and development
– 142
– 585
Other income
15
61
Other expense
– 113
– 126
Operating income/(loss) from discontinued operations
71
– 234
Interest expense
– 10
– 25
Other financial income and expense
– 3
– 1
Income/(loss) before taxes from discontinued operations
58
– 260
Taxes
– 159
74
Net loss from discontinued operations

before gain on distribution of Alcon Inc.

to Novartis AG shareholders




– 101




– 186
Gain on distribution of Alcon Inc. to Novartis AG shareholders  2
4 691
Net income/(loss) from discontinued operations
4 590
– 186
 1  The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off.
 2  See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders.
Consolidated income statement, additional information
(USD millions)
2019
2018
Interest income
2
Depreciation of property, plant and equipment
– 42
– 235
Depreciation of right-of-use assets
– 9
Amortization of intangible assets
– 174
– 1 052
Impairment charges on property, plant and equipment
– 3
Impairment charges on intangible assets  1
– 391
Additions to restructuring provisions
– 13
Equity-based compensation of Novartis equity plans
– 9
– 93
 1  2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc.
Respective Useful Lives of Available-for-Use Intangible Assets




Useful life
Income statement location

for amortization and

impairment charges
Marketing know-how
25 years
"Cost of goods sold"
Alcon brand name
Not amortized,

indefinite useful life
"Other expense"

Balance sheet, additional information
(USD millions)
2019
Additions to property, plant and equipment
113
Additions to right-of-use assets
3
Additions to goodwill and intangible assets
36
 
Cash flows used in investing activities
(USD millions)
2020
2019
2018
Payments attributable

to the spin-off of the

Alcon business




– 39




– 29




Divested cash and cash equivalents
– 628
Cash flows attributable to the spin-off of the Alcon business
– 39
– 657
Other cash flows used in investing activities, net
– 88
– 502
– 1 001
Net cash flows used in investing activities from discontinued operations
– 127
– 1 159
– 1 001
Disclosure of net assets derecognized
(USD millions)
2019
Property, plant and equipment
2 858
Right-of-use assets
269
Goodwill
8 906
Intangible assets other than goodwill
11 121
Deferred tax assets
732
Financial and other non-current assets
526
Inventories
1 469
Trade receivables and other current assets
1 787
Cash and cash equivalents
628
Deferred tax liabilities
– 1 713
Current and non-current lease liabilities
– 269
Current and non-current financial debts
– 3 538
Trade payables, provisions and other liabilities
– 2 751
Net assets derecognized
20 025
Defined contribution plans
(USD millions)
2019
2018
Contributions for defined contribution plans discontinued operations
33
104